Fjarde AP Fonden Fourth Swedish National Pension Fund Reduces Holdings in Illumina, Inc. (NASDAQ:ILMN)

Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its position in Illumina, Inc. (NASDAQ:ILMN) by 13.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 34,886 shares of the life sciences company’s stock after selling 5,400 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Illumina were worth $4,662,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Empowered Funds LLC grew its holdings in shares of Illumina by 1.7% during the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after buying an additional 66 shares during the last quarter. Bank of Stockton grew its position in Illumina by 3.8% in the 4th quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock valued at $289,000 after buying an additional 80 shares during the last quarter. Caprock Group LLC raised its position in Illumina by 3.0% during the 3rd quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after buying an additional 83 shares during the last quarter. Integrated Advisors Network LLC lifted its stake in shares of Illumina by 2.0% in the 3rd quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after acquiring an additional 90 shares during the period. Finally, Stephens Inc. AR boosted its holdings in shares of Illumina by 1.4% in the fourth quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock valued at $885,000 after acquiring an additional 90 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the topic of a number of analyst reports. Citigroup lowered Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. Robert W. Baird increased their price objective on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Stephens upped their price target on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Piper Sandler boosted their price objective on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, Royal Bank of Canada dropped their target price on shares of Illumina from $250.00 to $247.00 and set an “outperform” rating for the company in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $159.45.

Illumina Stock Performance

Illumina stock opened at $95.73 on Wednesday. The stock has a fifty day moving average price of $126.02 and a 200 day moving average price of $133.80. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52 week low of $91.92 and a 52 week high of $156.66. The firm has a market capitalization of $15.16 billion, a P/E ratio of -12.46, a PEG ratio of 1.60 and a beta of 1.10.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.